

Expression of androgen receptor splice variants in clinical

Oncotarget

6, 44728-44744

DOI: [10.18632/oncotarget.6296](https://doi.org/10.18632/oncotarget.6296)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Androgen Receptor: A Complex Therapeutic Target for Breast Cancer. <i>Cancers</i> , 2016, 8, 108.	1.7	49
2	Androgen and breast cancer. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2016, 23, 249-256.	1.2	15
3	Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. <i>Nature Communications</i> , 2016, 7, 13668.	5.8	134
4	Up-regulated expression of scavenger receptor class B type 1 (SR-B1) is associated with malignant behaviors and poor prognosis of breast cancer. <i>Pathology Research and Practice</i> , 2016, 212, 555-559.	1.0	29
5	Androgen receptor signaling pathways as a target for breast cancer treatment. <i>Endocrine-Related Cancer</i> , 2016, 23, R485-R498.	1.6	78
6	Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. <i>Endocrine-Related Cancer</i> , 2016, 23, T179-T197.	1.6	132
7	Family Matters: Collaboration and Conflict Among the Steroid Receptors Raises a Need for Group Therapy. <i>Endocrinology</i> , 2016, 157, 4553-4560.	1.4	15
9	Sigma1 Targeting to Suppress Aberrant Androgen Receptor Signaling in Prostate Cancer. <i>Cancer Research</i> , 2017, 77, 2439-2452.	0.4	32
10	Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer. <i>Cancer Research</i> , 2017, 77, 3417-3430.	0.4	79
11	Androgen Receptor in Health and Disease. , 2017, , 21-73.		2
12	MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. <i>Cancer Research</i> , 2017, 77, 1021-1034.	0.4	94
13	Androgen receptor in estrogen receptor positive breast cancer: Beyond expression. <i>Cancer Treatment Reviews</i> , 2017, 61, 15-22.	3.4	43
14	Lacrimal gland ductal carcinomas: Clinical, Morphological and Genetic characterization and implications for targeted treatment. <i>Acta Ophthalmologica</i> , 2017, 95, 299-306.	0.6	24
15	C-terminally truncated constitutively active androgen receptor variants and their biologic and clinical significance in castration-resistant prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 166, 38-44.	1.2	17
16	Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms. <i>Oncogene</i> , 2017, 36, 2775-2790.	2.6	78
17	Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 269-283.	12.5	36
18	AR-Signaling in Human Malignancies: Prostate Cancer and Beyond. <i>Cancers</i> , 2017, 9, 7.	1.7	49
19	Novel Nine-Exon AR Transcripts (Exon 1/Exon 1b/Exons 2â€“8) in Normal and Cancerous Breast and Prostate Cells. <i>International Journal of Molecular Sciences</i> , 2017, 18, 40.	1.8	15

#	ARTICLE	IF	CITATIONS
20	Targeting the androgen receptor in triple-negative breast cancer: current perspectives. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4675-4685.	1.0	48
21	AR Expression in Breast Cancer CTCs Associates with Bone Metastases. <i>Molecular Cancer Research</i> , 2018, 16, 720-727.	1.5	68
22	Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer. <i>Hormones and Cancer</i> , 2018, 9, 82-94.	4.9	21
23	Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 125, 51-59.	2.0	8
24	Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. <i>European Urology</i> , 2018, 74, 562-572.	0.9	80
25	Ethanol Extracts from <i>Azadirachta indica</i> Leaves Modulate Transcriptional Levels of Hormone Receptor Variant in Breast Cancer Cell Lines. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1879.	1.8	4
27	Consideration of breast cancer subtype in targeting the androgen receptor. , 2019, 200, 135-147.		65
28	MicroRNAs and Androgen Receptor: Emerging Players in Breast Cancer. <i>Frontiers in Genetics</i> , 2019, 10, 203.	1.1	19
29	Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms. <i>Journal of Hematology and Oncology</i> , 2019, 12, 38.	6.9	66
30	A magic drug target: Androgen receptor. <i>Medicinal Research Reviews</i> , 2019, 39, 1485-1514.	5.0	44
31	Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 29-42.	1.1	11
32	Role of androgen receptor splice variants, their clinical relevance and treatment options. <i>World Journal of Urology</i> , 2020, 38, 647-656.	1.2	21
34	Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 497-509.	2.4	31
35	TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2111-2123.	3.2	91
36	Circulating Tumor Cells Expressing the Prostate Specific Membrane Antigen (PSMA) Indicate Worse Outcome in Primary, Non-Metastatic Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1658.	1.3	17
37	Glycogen-rich Clear Cell Carcinoma of the Breast: A Comprehensive Review. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 655-660.	0.6	7
38	ARe we there yet? Understanding androgen receptor signaling in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 47.	2.3	57
39	Quadruple-negative breast cancer: novel implications for a new disease. <i>Breast Cancer Research</i> , 2020, 22, 127.	2.2	17

#	ARTICLE	IF	CITATIONS
40	Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1083.	1.3	10
41	Androgen Receptor in Breast Cancer: From Bench to Bedside. <i>Frontiers in Endocrinology</i> , 2020, 11, 573.	1.5	31
42	A Multi-Analyte Approach for Improved Sensitivity of Liquid Biopsies in Prostate Cancer. <i>Cancers</i> , 2020, 12, 2247.	1.7	18
43	Androgen Receptors in the Pathology of Disease. , 2021, , 411-461.		0
44	Depletion of androgen receptor low molecular weight isoform reduces bladder tumor cell viability and induces apoptosis. <i>Cancer Letters</i> , 2021, 504, 49-57.	3.2	5
45	Differential Expression of the Androgen Receptor, Splice Variants and Relaxin 2 in Renal Cancer. <i>Life</i> , 2021, 11, 731.	1.1	6
46	Steroid Receptors in Breast Cancer: Understanding of Molecular Function as a Basis for Effective Therapy Development. <i>Cancers</i> , 2021, 13, 4779.	1.7	11
47	Molecular Pathology of Breast Tumors. <i>Surgical Pathology Clinics</i> , 2021, 14, 455-471.	0.7	2
48	Androgen receptor splice variant-7 in breast cancer: clinical and pathologic correlations. <i>Modern Pathology</i> , 2022, 35, 396-402.	2.9	9
49	Androgens, oestrogens and endometrium: a fine balance between perfection and pathology. <i>Journal of Endocrinology</i> , 2020, 246, R75-R93.	1.2	41
50	Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer. <i>Oncotarget</i> , 2016, 7, 50507-50521.	0.8	44
51	Estrogen and androgen-converting enzymes 17 β -hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17 β -hydroxysteroid dehydrogenase type 1, 2, and breast cancer. <i>Oncotarget</i> , 2017, 8, 30552-30562.	0.8	85
52	Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin. <i>Oncotarget</i> , 2016, 7, 23498-23511.	0.8	25
53	Androgen/androgen receptor axis maintains and promotes cancer cell stemness through direct activation of Nanog transcription in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 36814-36828.	0.8	28
55	Breast cancer molecular subtypes: from TNBC to QNBC. <i>American Journal of Cancer Research</i> , 2016, 6, 1864-1872.	1.4	65
56	Steroid hormone receptors as prognostic markers in breast cancer. <i>American Journal of Cancer Research</i> , 2017, 7, 1617-1636.	1.4	21
57	Androgen receptor gene mutations in 258 Han Chinese patients with polycystic ovary syndrome. <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 31.	0.8	1
58	Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Ralaniten Analogs for the Treatment of Androgen Receptorâ€“positive Prostate and Breast Cancers. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 294-309.	1.9	7

#	ARTICLE	IF	CITATIONS
59	Is It Time to Consider the Androgen Receptor as a Therapeutic Target in Breast Cancer?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 775-786.	0.9	7
60	Androgen receptor gene mutations in 258 Han Chinese patients with polycystic ovary syndrome. <i>Experimental and Therapeutic Medicine</i> , 2020, 21, 1-1.	0.8	7
61	An Update on the Molecular and Clinical Characteristics of Apocrine Carcinoma of the Breast. <i>Clinical Breast Cancer</i> , 2022, 22, e576-e585.	1.1	15
66	Adaptation to Hypoxia May Promote Therapeutic Resistance to Androgen Receptor Inhibition in Triple-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8844.	1.8	4
67	Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 341-351.	1.1	7
68	Drugging the Undruggable: Targeting the N-Terminal Domain of Nuclear Hormone Receptors. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 311-326.	0.8	1
72	Androgen Receptor in Health and Disease. , 2023, , 21-75.		0